TissueVision

Executive Summary

TissueVision is a Boston-area life sciences imaging solutions provider specializing in contract research for whole tissue and organ 3D imaging and analysis. Founded by experts from MIT, the company leverages its patented Serial Two Photon Tomography (STPT) technology and TissueCyte® platforms to offer scalable, high-throughput services to pharmaceutical, biotech, and academic clients. Its mission is to accelerate research and drug development by providing detailed histological data and quantitative analysis from large-scale tissue studies. The company's location in Cambridge, a biotech hub, positions it well to serve leading research institutions and drug developers. The market for advanced tissue imaging is growing as drug developers seek more comprehensive preclinical data to reduce late-stage failures. TissueVision's unique STPT technology enables high-resolution 3D imaging of entire organs, providing insights that traditional 2D histology cannot. With increasing demand for quantitative tissue analysis in neuroscience, oncology, and other therapeutic areas, TissueVision is poised for growth. The company's contract research model reduces capital barriers for clients and allows it to build long-term partnerships. However, as a private company with limited public information, visibility into upcoming milestones is constrained. Nevertheless, its proprietary technology and respected team suggest strong potential for continued expansion.

Upcoming Catalysts (preview)

• H2 2026Major Pharma Partnership for Drug Development Programs60% success
• 2027Launch of Next-Generation TissueCyte Imaging Platform40% success
• 2026Series A or B Funding Round to Scale Operations50% success